113 related articles for article (PubMed ID: 35461070)
1. The novel mechanism of Med12-mediated drug resistance in a TGFBR2-independent manner.
Han Y; Dong Q; Liu T; Chen X; Yu C; Zhang Y
Biochem Biophys Res Commun; 2022 Jun; 610():1-7. PubMed ID: 35461070
[TBL] [Abstract][Full Text] [Related]
2. Loss of MED12 activates the TGFβ pathway to promote chemoresistance and replication fork stability in BRCA-deficient cells.
Jackson LM; Dhoonmoon A; Hale A; Dennis KA; Schleicher EM; Nicolae CM; Moldovan GL
Nucleic Acids Res; 2021 Dec; 49(22):12855-12869. PubMed ID: 34871431
[TBL] [Abstract][Full Text] [Related]
3. The emerging role of mediator complex subunit 12 in tumorigenesis and response to chemotherapeutics.
Zhang S; O'Regan R; Xu W
Cancer; 2020 Mar; 126(5):939-948. PubMed ID: 31869450
[TBL] [Abstract][Full Text] [Related]
4. MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling.
Huang S; Hölzel M; Knijnenburg T; Schlicker A; Roepman P; McDermott U; Garnett M; Grernrum W; Sun C; Prahallad A; Groenendijk FH; Mittempergher L; Nijkamp W; Neefjes J; Salazar R; Ten Dijke P; Uramoto H; Tanaka F; Beijersbergen RL; Wessels LF; Bernards R
Cell; 2012 Nov; 151(5):937-50. PubMed ID: 23178117
[TBL] [Abstract][Full Text] [Related]
5. NEAT1 repression by MED12 creates chemosensitivity in p53 wild-type breast cancer cells.
Zhang S; Kim EJ; Huang J; Liu P; Donahue K; Wang Q; Wang Y; Mcilwain S; Xie L; Chen X; Li L; Xu W
FEBS J; 2024 May; 291(9):1909-1924. PubMed ID: 38380720
[TBL] [Abstract][Full Text] [Related]
6. TGF-β-SMAD-miR-520e axis regulates NSCLC metastasis through a TGFBR2-mediated negative-feedback loop.
Kucuksayan H; Akgun S; Ozes ON; Alikanoglu AS; Yildiz M; Dal E; Akca H
Carcinogenesis; 2019 Jul; 40(5):695-705. PubMed ID: 30475986
[TBL] [Abstract][Full Text] [Related]
7.
Siraj AK; Masoodi T; Bu R; Pratheeshkumar P; Al-Sanea N; Ashari LH; Abduljabbar A; Alhomoud S; Al-Dayel F; Alkuraya FS; Al-Kuraya KS
Gut; 2018 Apr; 67(4):663-671. PubMed ID: 28183795
[TBL] [Abstract][Full Text] [Related]
8. Silencing Med12 Gene Reduces Proliferation of Human Leiomyoma Cells Mediated via Wnt/β-Catenin Signaling Pathway.
Al-Hendy A; Laknaur A; Diamond MP; Ismail N; Boyer TG; Halder SK
Endocrinology; 2017 Mar; 158(3):592-603. PubMed ID: 27967206
[TBL] [Abstract][Full Text] [Related]
9. MED12 methylation by CARM1 sensitizes human breast cancer cells to chemotherapy drugs.
Wang L; Zeng H; Wang Q; Zhao Z; Boyer TG; Bian X; Xu W
Sci Adv; 2015 Oct; 1(9):e1500463. PubMed ID: 26601288
[TBL] [Abstract][Full Text] [Related]
10. TGFBR2‑dependent alterations of microRNA profiles in extracellular vesicles and parental colorectal cancer cells.
Fricke F; Mussack V; Buschmann D; Hausser I; Pfaffl MW; Kopitz J; Gebert J
Int J Oncol; 2019 Oct; 55(4):925-937. PubMed ID: 31432155
[TBL] [Abstract][Full Text] [Related]
11. Loss of MED12 Induces Tumor Dormancy in Human Epithelial Ovarian Cancer via Downregulation of EGFR.
Luo XL; Deng CC; Su XD; Wang F; Chen Z; Wu XP; Liang SB; Liu JH; Fu LW
Cancer Res; 2018 Jul; 78(13):3532-3543. PubMed ID: 29735544
[TBL] [Abstract][Full Text] [Related]
12. Mediator complex subunit 16 is down-regulated in papillary thyroid cancer, leading to increased transforming growth factor-β signaling and radioiodine resistance.
Gao H; Bai P; Xiao L; Shen M; Yu Q; Lei Y; Huang W; Lin X; Zheng X; Wei T; Jiang Y; Ye F; Bu H
J Biol Chem; 2020 Jul; 295(31):10726-10740. PubMed ID: 32532820
[TBL] [Abstract][Full Text] [Related]
13. MED12 exerts an emerging role in actin-mediated cytokinesis via LIMK2/cofilin pathway in NSCLC.
Xu M; Wang F; Li G; Wang X; Fang X; Jin H; Chen Z; Zhang J; Fu L
Mol Cancer; 2019 May; 18(1):93. PubMed ID: 31072327
[TBL] [Abstract][Full Text] [Related]
14. MiR-17-5p regulates cell proliferation and migration by targeting transforming growth factor-β receptor 2 in gastric cancer.
Qu Y; Zhang H; Duan J; Liu R; Deng T; Bai M; Huang D; Li H; Ning T; Zhang L; Wang X; Ge S; Zhou L; Zhong B; Ying G; Ba Y
Oncotarget; 2016 May; 7(22):33286-96. PubMed ID: 27120811
[TBL] [Abstract][Full Text] [Related]
15. A super-enhancer controls TGF- β signaling in pancreatic cancer through downregulation of TGFBR2.
Zhu X; Zhang T; Zhang Y; Chen H; Shen J; Jin X; Wei J; Zhang E; Xiao M; Fan Y; Mao R; Zhou G
Cell Signal; 2020 Feb; 66():109470. PubMed ID: 31730895
[TBL] [Abstract][Full Text] [Related]
16. Loss of TGF-β signaling in osteoblasts increases basic-FGF and promotes prostate cancer bone metastasis.
Meng X; Vander Ark A; Daft P; Woodford E; Wang J; Madaj Z; Li X
Cancer Lett; 2018 Apr; 418():109-118. PubMed ID: 29337106
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanism of miR-153 inhibiting migration, invasion and epithelial-mesenchymal transition of breast cancer by regulating transforming growth factor beta (TGF-β) signaling pathway.
Wang J; Liang S; Duan X
J Cell Biochem; 2019 Jun; 120(6):9539-9546. PubMed ID: 30525231
[TBL] [Abstract][Full Text] [Related]
18. Identification of miR-135b as a novel regulator of TGFβ pathway in gastric cancer.
Bai M; Wang P; Yang J; Zuo M; Ba Y
J Physiol Biochem; 2020 Nov; 76(4):549-560. PubMed ID: 32737704
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic exon 2 mutations in Mediator subunit MED12 disrupt allosteric activation of cyclin C-CDK8/19.
Park MJ; Shen H; Spaeth JM; Tolvanen JH; Failor C; Knudtson JF; McLaughlin J; Halder SK; Yang Q; Bulun SE; Al-Hendy A; Schenken RS; Aaltonen LA; Boyer TG
J Biol Chem; 2018 Mar; 293(13):4870-4882. PubMed ID: 29440396
[TBL] [Abstract][Full Text] [Related]
20. TGF-beta receptor type-2 expression in cancer-associated fibroblasts regulates breast cancer cell growth and survival and is a prognostic marker in pre-menopausal breast cancer.
Busch S; Acar A; Magnusson Y; Gregersson P; Rydén L; Landberg G
Oncogene; 2015 Jan; 34(1):27-38. PubMed ID: 24336330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
